Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene for Smoking Cessation
NCT00202696Phase 2Completed
- Sponsor
- Somaxon Pharmaceuticals, Inc.
- Start
- Sep 2005
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nalmefene in nicotine dependence (3 arms), sponsored by Somaxon Pharmaceuticals, Inc. Primary endpoint: Efficacy of nalmefene relative to placebo. Started Sep 2005; status: completed.
02
Drugs
nalmefene
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00202696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202696.